This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berthold, D. R. Articles by Tannock, I. F. Search for Related Content PubMed Articles by Berthold, D. R. Articles by Tannock, I. F. Social Bookmarking                            What's this?

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

Dominik R. Berthold, Gregory R. Pond, Freidele Soban, Ronald de Wit, Mario Eisenberger, Ian F. Tannock

From the Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada; Erasmus University Medical Center, Rotterdam, the Netherlands; and Sydney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

Corresponding author: Ian F. Tannock, MD, PhD, FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada; e-mail: ian.tannock{at}uhn.on.ca

Purpose The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant prostate cancer (HRPC). The original analysis, undertaken in August 2003 when 557 deaths had occurred, showed significantly better survival and response rates for pain, prostate-specific antigen (PSA), and quality of life for D3P when compared with MP. Here, we report an updated analysis of survival.

Methods Investigators were asked to provide the date of death or last follow-up for all participants who were alive in August 2003.

Results By March 2007, data on 310 additional deaths were obtained (total = 867 deaths). The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004). Median survival time was 19.2 months (95% CI, 17.5 to 21.3 months) in the D3P arm, 17.8 months (95% CI, 16.2 to 19.2 months) in the D1P arm, and 16.3 months (95% CI, 14.3 to 17.9 months) in the MP arm. More patients survived 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%). Similar trends in survival between treatment arms were seen for men greater than and less than 65 years of age, for those with and without pain at baseline, and for those with baseline PSA greater than and less than the median value of 115 ng/mL.

Conclusion The present analysis confirms that survival of men with metastatic HRPC is significantly longer after treatment with D3P than with MP. Consistent results are observed across subgroups of patients.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. N. Sternberg, D. P. Petrylak, O. Sartor, J. A. Witjes, T. Demkow, J.-M. Ferrero, J.-C. Eymard, S. Falcon, F. Calabro, N. James, et al. Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial J. Clin. Oncol., November 10, 2009; 27(32): 5431 - 5438. [Abstract] [Full Text] [PDF]

				C. G. Drake Immunotherapy for Prostate Cancer: Walk, Don't Run J. Clin. Oncol., September 1, 2009; 27(25): 4035 - 4037. [Full Text] [PDF]

				A. J. Armstrong and P. G. Febbo Using Surrogate Biomarkers to Predict Clinical Benefit in Men with Castration-Resistant Prostate Cancer: An Update and Review of the Literature Oncologist, August 1, 2009; 14(8): 816 - 827. [Abstract] [Full Text] [PDF]

				G. Sonpavde, P. O. Periman, D. Bernold, D. Weckstein, M. T. Fleming, M. D. Galsky, W. R. Berry, F. Zhan, K. A. Boehm, L. Asmar, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy Ann. Onc., July 24, 2009; (2009) mdp323v1. [Abstract] [Full Text] [PDF]

				C. N. Sternberg, H. Dumez, H. Van Poppel, I. Skoneczna, A. Sella, G. Daugaard, T. Gil, J. Graham, P. Carpentier, F. Calabro, et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer Ann. Onc., July 1, 2009; 20(7): 1264 - 1269. [Abstract] [Full Text] [PDF]

				K. Fizazi, P. Beuzeboc, J. Lumbroso, V. Haddad, C. Massard, M. Gross-Goupil, M. Di Palma, B. Escudier, C. Theodore, Y. Loriot, et al. Phase II Trial of Consolidation Docetaxel and Samarium-153 in Patients With Bone Metastases From Castration-Resistant Prostate Cancer J. Clin. Oncol., May 20, 2009; 27(15): 2429 - 2435. [Abstract] [Full Text] [PDF]

				J.-P. Machiels, F. Mazzeo, M. Clausse, B. Filleul, L. Marcelis, B. Honhon, L. D'Hondt, C. Dopchie, V. Verschaeve, L. Duck, et al. Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer J. Clin. Oncol., November 10, 2008; 26(32): 5261 - 5268. [Abstract] [Full Text] [PDF]

				D. R. Berthold, G. R. Pond, R. de Wit, M. Eisenberger, I. F. Tannock, and On behalf of the TAX 327 investigators Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa Ann. Onc., October 1, 2008; 19(10): 1749 - 1753. [Abstract] [Full Text] [PDF]

				A. J. Armstrong, P. Creel, J. Turnbull, C. Moore, T. A. Jaffe, S. Haley, W. Petros, S. Yenser, J. P. Gockerman, D. Sleep, et al. A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6270 - 6276. [Abstract] [Full Text] [PDF]

				C. Nabhan Is Chemotherapy the Standard for Asymptomatic Androgen-Independent Prostate Cancer? J. Clin. Oncol., May 10, 2008; 26(14): 2413 - 2414. [Full Text] [PDF]

				D. Berthold and I. Tannock In Reply J. Clin. Oncol., May 10, 2008; 26(14): 2414 - 2415. [Full Text] [PDF]

				A. J. Armstrong, E. L. Garrett-Mayer, and M. Eisenberger Re: Adaptive Therapy for Androgen-Independent Prostate Cancer: A Randomized Selection Trial of Four Regimens J Natl Cancer Inst, May 7, 2008; 100(9): 681 - 682. [Full Text] [PDF]

				D. R. Berthold, G. R. Pond, M. Roessner, R. de Wit, M. Eisenberger, a. I. F. Tannock, and on behalf of the TAX-327 investigators Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study Clin. Cancer Res., May 1, 2008; 14(9): 2763 - 2767. [Abstract] [Full Text] [PDF]

				Long-Term Survival of Men Treated with Docetaxel and Prednisone for Prostate Cancer Journal Watch Oncology and Hematology, February 5, 2008; 2008(205): 1 - 1. [Full Text]